Drug Effectiveness Report: "HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin"

Case ID:
1675
Web Published:
1/29/2015
Description:

In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.

Patent Information:
Category(s):
Education & Training
For Information, Contact:
Michele Gunness
Senior Technology Development Manager
Oregon Health & Science University
(503) 494-8200
gunnessm@ohsu.edu
Inventors:
Drug Effectiveness Review Project
Keywords:
Education & Training
Education & Training - Clinical
Education & Training - Other
© 2018. All Rights Reserved. Powered by Inteum